Back to today’s briefing

Story perspectives

Sarepta Faces Crisis: FDA Halts Gene Therapy After Deaths

7/20/2025

44 9

Summary

Story summary

Sarepta Therapeutics is grappling with a crisis as the FDA halts shipments of its gene therapy, Elevidys, after three patients tragically succumbed to acute liver failure. In response, the company is slashing its workforce by 36% and restructuring amid plummeting stock prices, leaving the future of Elevidys in jeopardy as safety concerns loom large.

1 of 1

Story summary

Sarepta Therapeutics is grappling with a crisis as the FDA halts shipments of its gene therapy, Elevidys, after three patients tragically succumbed to acute liver failure. In response, the company is slashing its workforce by 36% and restructuring amid plummeting stock prices, leaving the future of Elevidys in jeopardy as safety concerns loom large.